ANI secures FTC clearance to acquire Novitium

The acquisition is expected to be completed on or about Nov. 18.

11/12/2021

ANI today announced that the Federal Trade Commission has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma.

The companies, which announced their $210 million deal in March, agreed to sell ANI's development rights to generic sulfamethoxazole-trimethoprim oral suspension, a combination of antibiotics and assets related to generic dexamethasone, used to treat inflammation and arthritis, according to a Reuters report.

The company noted that the divestitures required by the FTC of development rights to one generic drug and assets with respect to another generic drug are immaterial to the company’s business.

ANI expects that the acquisition will be completed on or about Nov. 18, 2021.

[Read more: ANI launches prazosin capsules]

Related Topics